Compare FRAF & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | KOD |
|---|---|---|
| Founded | 1906 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.9M | 2.8B |
| IPO Year | 1995 | 2018 |
| Metric | FRAF | KOD |
|---|---|---|
| Price | $58.51 | $35.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $35.43 |
| AVG Volume (30 Days) | 20.7K | ★ 524.8K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $38.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.44 | $3.35 |
| 52 Week High | $60.00 | $47.84 |
| Indicator | FRAF | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 39.39 |
| Support Level | $54.63 | $32.93 |
| Resistance Level | $58.77 | $46.72 |
| Average True Range (ATR) | 1.80 | 2.69 |
| MACD | 0.06 | -0.72 |
| Stochastic Oscillator | 80.06 | 16.94 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.